Healthcare & pharmaceutical equity investment research - Page 2

Healthcare Insights

Market cap

Date (published)

thematic

Healthcare

04.01.23

Oncology ABCs (part four): Blood cancers (AML) – notable innovations

thematic

Healthcare

26.01.23

Machine learning in drug development

Healthcare

thematic

13.06.23

ASCO 2023 key takeaways

Latest

Healthcare | insight

28.11.23

Incannex’s US redomicile is now complete – what’s next?

Healthcare | Update

27.11.23

AFT Pharmaceuticals — Global growth despite tough macro environment

Healthcare | Flash note

27.11.23

OSE Immunotherapeutics — Collaboration bolsters upcoming Tedopi Phase III

Healthcare | Flash note

27.11.23

Oryzon Genomics — Key €45m funding to back strategic priorities

insight

Healthcare

18.05.23

Incannex Healthcare: Data opens path to treat anxiety

insight

Healthcare

09.02.23

February 2023 Edition of Edison Healthcare Insight

insight

Healthcare

30.01.23

VolitionRx: Commercializing the Nu.Q Vet Cancer Test: Webinar

insight

Healthcare

20.12.22

Encouraging top-line data from Unyvero urinary tract infection (UTI) panel

insight

Healthcare

09.12.22

Healthcare Week 2023

insight

Healthcare

08.12.22

December 2022 edition of Edison Healthcare Insight

Analyst of the week

Soo Romanoff

Managing Director - Head of Content, Healthcare

sromanoff@edisongroup.com 020 3077 5700

Read latest

Equities

Region

Market cap

OpGen (OPGN)

Latest price

USD0.46

▾ 0.04 (9.52)

As at 28/11/2023

Market capitalisation: USD4m

View equity

Update

Healthcare

14.08.23

OpGen — Cash concerns dampen active Q2

Flash note

Healthcare

04.08.23

OpGen — FIND collaboration advances to development

Flash note

Healthcare

21.07.23

OpGen — Feasibility milestone from FIND collaboration

See more
content on

OpGen

Oryzon Genomics (ORY)

Latest price

EUR2.05

▾ 0.03 (1.49)

As at 28/11/2023

Market capitalisation: EUR118m

View equity

Flash note

Healthcare

27.11.23

Oryzon Genomics — Key €45m funding to back strategic priorities

Update

Healthcare

06.11.23

Oryzon Genomics — Q323 recap ahead of key clinical stages

Flash note

Healthcare

11.10.23

Oryzon Genomics — Favorable safety reported in PORTICO Phase II

See more
content on

Oryzon Genomics

OSE Immunotherapeutics (OSE)

Latest price

EUR4.07

▾ −0.23 (−5.35)

As at 28/11/2023

Market capitalisation: EUR92m

View equity

Flash note

Healthcare

27.11.23

OSE Immunotherapeutics — Collaboration bolsters upcoming Tedopi Phase III

Flash note

Healthcare

17.10.23

OSE Immunotherapeutics — Anticipation builds with positive OSE-279 data

Update

Healthcare

03.10.23

OSE Immunotherapeutics — Maintaining momentum after an active H123

See more
content on

OSE Immunotherapeutics

Oxford Cannabinoid Technologies (OCTP)

Latest price

GBP0.01

▾ 0.08 (12.31)

As at 28/11/2023

Market capitalisation: GBP6m

View equity

Flash note

Healthcare

12.10.23

Oxford Cannabinoid Technologies — Poised to progress to Phase II pending raise

Update

Healthcare

12.09.23

Oxford Cannabinoid Technologies — Clinical headway rests on funding

Initiation

Healthcare

17.07.23

Oxford Cannabinoid Technologies — A move away from generic pain treatment

See more
content on

Oxford Cannabinoid Technologies

Paradigm Biopharma (PAR)

Latest price

AUD0.39

▾ −0.01 (−1.28)

As at 28/11/2023

Market capitalisation: AUD141m

View equity

Update

Healthcare

02.11.23

Paradigm Biopharmaceuticals — Q1 results recap iPPS progress in OA & MPS

Flash note

Healthcare

25.10.23

Paradigm Biopharma — Disease modifying properties in iPPS Phase II

Update

Healthcare

17.10.23

Paradigm Biopharma — Durable responses observed for kOA

See more
content on

Paradigm Biopharma

Pharnext (ALPHA)

Latest price

EUR0.10

▾ 0.03 (42.86)

As at 28/11/2023

Market capitalisation: EUR1m

View equity

Flash note

Healthcare

25.09.23

Pharnext — Potential licensing deals could add confidence

Update

Healthcare

22.05.23

Pharnext — Improving FY23 financial footing

Update

06.03.23

Pharnext — Revised legal structure to offer operational stability

See more
content on

Pharnext

Pixium Vision (PIX)

Latest price

EUR0.15

▾ −0.04 (−21.05)

As at 28/11/2023

Market capitalisation: EUR1m

View equity

Flash note

Healthcare

10.10.23

Pixium Vision — Safeguard proceedings underway

Update

Healthcare

11.08.23

Pixium Vision — Shareholder loan extends runway

Update

Healthcare

02.05.23

Pixium Vision — Focusing on reaching the PRIMAvera milestone

See more
content on

Pixium Vision

Recce Pharmaceuticals (RCE)

Latest price

AUD0.44

— 0.00 (0.00)

As at 28/11/2023

Market capitalisation: AUD93m

View equity

Team of Research Scientists Working On Computer, with Medical Equipment, Analyzing Blood and Genetic Material Samples with Special Machines in the Modern Laboratory.

Update

Healthcare

23.08.23

Recce Pharmaceuticals — R327 progressing in rapid infusion study

Update

Healthcare

11.07.23

Recce Pharmaceuticals — Gearing up for more R327 studies

Initiation

Healthcare

08.03.23

Recce Pharmaceuticals — Seeking a breakthrough in sepsis

See more
content on

Recce Pharmaceuticals

Renaissance BioScience (RENABIOTICKER)

Latest price

—

— 0.00 (0.00)

As at 28/11/2023

Market capitalisation: —

View equity

QuickView

Healthcare

21.01.22

Renaissance BioScience — RNAi technology from bioengineered yeast

See more
content on

Renaissance BioScience

ReNeuron Group (RENE)

Latest price

GBP0.04

▾ 0.12 (2.91)

As at 28/11/2023

Market capitalisation: GBP2m

View equity

Update

Healthcare

27.11.23

ReNeuron Group — H124 results reaffirm focus on CustomEX

Flash note

Healthcare

15.09.23

ReNeuron Group — A step forward on the Exosome delivery platform

Update

Healthcare

30.05.23

ReNeuron Group — Full steam ahead with CustomEx

See more
content on

ReNeuron Group

Respiri (RSH)

Latest price

AUD0.03

▾ −0.01 (−15.63)

As at 28/11/2023

Market capitalisation: AUD31m

View equity

Update

Healthcare

12.09.23

Respiri — Access platform-led growth prospects ahead

Happy children launch a kite in the field at sunset. Little boy and girl on summer vacation

Flash note

Healthcare

30.08.23

Respiri — Early onset of synergies from Access acquisition

Flash note

Healthcare

14.08.23

Respiri — Raise anticipated to fund the Access acquisition

See more
content on

Respiri

Sareum Holdings (SAR)

Latest price

GBP0.60

— 0.00 (0.00)

As at 28/11/2023

Market capitalisation: GBP44m

View equity

Update

Healthcare

02.11.23

Paradigm Biopharmaceuticals — Q1 results recap iPPS progress in OA & MPS

Flash note

Healthcare

25.10.23

Paradigm Biopharma — Disease modifying properties in iPPS Phase II

Update

TMT

24.10.23

Freelancer — Delivering on cash and profit targets

See more
content on

Sareum Holdings

Sequana Medical (SEQUA)

Latest price

EUR2.46

▾ −0.04 (−1.60)

As at 28/11/2023

Market capitalisation: EUR68m

View equity

Close up of Doctor is showing medical analytics data of Coronavirus (Covid-19), Medical technology concept

Update

Healthcare

13.11.23

Sequana Medical — MOJAVE early efficacy validates DSR 2.0

Update

Healthcare

25.09.23

Sequana Medical — On track to meet key milestones

Flash note

Healthcare

12.07.23

Sequana Medical — MOJAVE enrols first patient

See more
content on

Sequana Medical

Shield Therapeutics (STX)

Latest price

GBP0.06

▾ −0.20 (−3.33)

As at 28/11/2023

Market capitalisation: GBP49m

View equity

Update

Healthcare

29.09.23

Shield Therapeutics — Ramped up and heading into a stronger H223

Update

Healthcare

04.05.23

Shield Therapeutics — FY23 a key year for business traction

Flash note

Healthcare

10.02.23

Shield Therapeutics — Strategic year-end pivot sets tone for robust FY23

See more
content on

Shield Therapeutics

SIGA Technologies (SIGA)

Latest price

USD5.33

▾ −0.01 (−0.19)

As at 28/11/2023

Market capitalisation: USD368m

View equity

Update

Healthcare

09.11.23

SIGA Technologies — International momentum building towards year-end

Flash note

Healthcare

24.10.23

SIGA Technologies — EU gateway to tap into new international orders

Flash note

Healthcare

08.09.23

SIGA Technologies — Notable CMO appointment to position for growth

See more
content on

SIGA Technologies

Ultimovacs (ULTI)

Latest price

NOK116.00

▾ −3.80 (−3.17)

As at 28/11/2023

Market capitalisation: NOK3,902m

View equity

Update

Healthcare

09.11.23

Ultimovacs — Staying alive with UV1 in NIPU and INTIUM

Flash note

Healthcare

02.11.23

Ultimovacs — Line of sight on INITIUM top-line readout

research

Healthcare

18.10.23

Ultimovacs — Overall survival is the name of the NIPU PII game

See more
content on

Ultimovacs

Curated by Edison

singularityhub.com

The Next Step for AI in Biology Is to Predict How Proteins Behave in the Body

Healthcare

A new protein atlas can help turn static AI predictions of protein shapes into more fluid predictions of how proteins behave in the body.

Read article

www.genome.gov

The Cost of Sequencing a Human Genome

Healthcare

Estimated cost of sequencing the human genome over time since the Human Genome Project.

Read article

www.prnewswire.com

J.P. Morgan Launches New Life Sciences Private Capital Team Targeting Investments in Innovative Healthcare Companies

Healthcare

/PRNewswire/ -- J.P. Morgan Asset Management today announced the launch of a new life sciences private equity team, Life Sciences Private Capital. The new team...

Read article

insights.omnia-health.com

Leveraging nanotechnology to transform the disinfection industry

Healthcare

Co-founders of Kismet Technologies, Christina Drake and Shari Costantini, discuss how NanoRad, one of their flagship products, uses targeted application to kill a wide range of bacteria and viruses.

Read article

www.bain.com

2022 Healthcare Provider IT Report: Post-Pandemic Investment Priorities

Healthcare

As healthcare providers enter a new period of disruption, their software investment priorities present opportunities for vendors and investors.

Read article

Thematics

thematic

Healthcare

07.11.22

Oncology ABCs (part three) – thinking outside the box in women’s cancer

thematic

Healthcare

01.11.22

Neuroscience comeback

thematic

Consumer

05.10.22

IPO apocalypse

thematic

Healthcare

03.10.22

Oncology ABCs (part two) – vaccines: niche no longer

thematic

TMT

10.08.22

ESG, moving beyond the box tick

thematic

Healthcare

01.07.22

Oncology ABCs (part one) – a small-cap biopharma prospectus series

thematic

Healthcare

26.04.22

Cannabinoid manufacturing – Innovative approaches to the production of cannabinoids

thematic

Healthcare

10.11.21

Artificial intelligence in drug discovery

Equities

Equities by Sector

Sectors

Investment Strategy

Latest

Equity Strategy and Market outlook – October 2023

Equity strategy and market outlook – September 2023

Equity strategy and market outlook – August 2023

Thematics

Latest

Deutsches Eigenkapitalforum (EKF) 2023 consumer and media

Deutsches Eigenkapitalforum (EKF) 2023 technology

Deutsches Eigenkapitalforum (EKF) 2023 financials and investment companies

About Edison

About Edison

Careers

Healthcare

Incannex Healthcare

17.39%

Healthcare Insights

Oncology ABCs (part four): Blood cancers (AML) – notable innovations

Machine learning in drug development

ASCO 2023 key takeaways

Latest

Incannex’s US redomicile is now complete – what’s next?

AFT Pharmaceuticals — Global growth despite tough macro environment

OSE Immunotherapeutics — Collaboration bolsters upcoming Tedopi Phase III

Oryzon Genomics — Key €45m funding to back strategic priorities

Incannex Healthcare: Data opens path to treat anxiety

February 2023 Edition of Edison Healthcare Insight

VolitionRx: Commercializing the Nu.Q Vet Cancer Test: Webinar

Encouraging top-line data from Unyvero urinary tract infection (UTI) panel

Healthcare Week 2023

December 2022 edition of Edison Healthcare Insight

Analyst of the week

Equities

OpGen (OPGN)

USD0.46

OpGen — Cash concerns dampen active Q2

OpGen — FIND collaboration advances to development

OpGen — Feasibility milestone from FIND collaboration

See morecontent on

Oryzon Genomics (ORY)

EUR2.05

Oryzon Genomics — Key €45m funding to back strategic priorities

Oryzon Genomics — Q323 recap ahead of key clinical stages

Oryzon Genomics — Favorable safety reported in PORTICO Phase II

See morecontent on

OSE Immunotherapeutics (OSE)

EUR4.07

OSE Immunotherapeutics — Collaboration bolsters upcoming Tedopi Phase III

OSE Immunotherapeutics — Anticipation builds with positive OSE-279 data

OSE Immunotherapeutics — Maintaining momentum after an active H123

See morecontent on

Oxford Cannabinoid Technologies (OCTP)

GBP0.01

Oxford Cannabinoid Technologies — Poised to progress to Phase II pending raise

Oxford Cannabinoid Technologies — Clinical headway rests on funding

Oxford Cannabinoid Technologies — A move away from generic pain treatment

See morecontent on

Paradigm Biopharma (PAR)

AUD0.39

Paradigm Biopharmaceuticals — Q1 results recap iPPS progress in OA & MPS

Paradigm Biopharma — Disease modifying properties in iPPS Phase II

Paradigm Biopharma — Durable responses observed for kOA

See morecontent on

Pharnext (ALPHA)

EUR0.10

Pharnext — Potential licensing deals could add confidence

Pharnext — Improving FY23 financial footing

Pharnext — Revised legal structure to offer operational stability

See morecontent on

Pixium Vision (PIX)

EUR0.15

Pixium Vision — Safeguard proceedings underway

Pixium Vision — Shareholder loan extends runway

Pixium Vision — Focusing on reaching the PRIMAvera milestone

See morecontent on

Recce Pharmaceuticals (RCE)

AUD0.44

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on